Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Patient with Type 2 Diabetes
100%
Insulin
100%
Metformin Plus Rosiglitazone
100%
Bone Remodeling
100%
Placebo
66%
Glycon
66%
Maturity Onset Diabetes of the Young
50%
Hemoglobin A1c
50%
Rosiglitazone
50%
Osteolysis
33%
Bone Turnover
33%
Glycemic Control
33%
Ossification
16%
Body Mass Index
16%
Antidiabetic Agent
16%
Insulin Treatment
16%
Clinical Trial
16%
Kidney Function
16%
Hyperglycemia
16%
Steady State
16%
Recombinant Human Insulin
16%
Human Insulin
16%
Hypoinsulinemia
16%
Keyphrases
Insulin
100%
Type 2 Diabetic Patients
100%
Metformin
100%
Bone Metabolism
100%
Rosiglitazone
100%
Placebo
44%
Hemoglobin A1c (HbA1c)
33%
Fracture Risk
22%
Type 2 Diabetes Mellitus (T2DM)
22%
Glycemic Control
22%
Insulin Dose
22%
Bone Resorption
22%
Non-associated
11%
Plasma Concentration
11%
Bone Turnover Markers
11%
Bone Turnover
11%
Hyperglycemia
11%
Insulin Therapy
11%
Renal Function
11%
Steady-state Plasma Concentration
11%
Clinical Trials
11%
Human Insulin
11%
Pathophysiological Mechanisms
11%
Bone Formation
11%
Antidiabetic Treatment
11%
Mixed-effects Model
11%
Insulinopenia
11%
Antidiabetic Drug
11%
Metformin Treatment
11%
Pharmacology, Toxicology and Pharmaceutical Science
Insulin
100%
Metformin Plus Rosiglitazone
100%
Maturity Onset Diabetes of the Young
100%
Placebo
66%
Metformin
66%
Hemoglobin A1c
50%
Rosiglitazone
50%
Antidiabetic Agent
16%
Clinical Trial
16%
Recombinant Human Insulin
16%
Human Insulin
16%
Hyperglycemia
16%
Hypoinsulinemia
16%